血清CD40升高作为急性甲状腺毒性肌肉病变的差异诊断的潜在生物标志物
Chunjiao Wu1, Yun Zhang1, Tingliang Wang1
1Department of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Scientific reports
|March 12, 2025
概括
血清CD40水平可以帮助诊断急性甲状腺毒性肌病 (ATM),甲状腺毒性病的严重并发症. 增加的CD40与ATM症状严重程度相关,为早期诊断提供了潜在的生物标志物,并将其与格雷夫斯病区分开来.
科学领域:
- 内分泌学 在内分泌学.
- 免疫学 免疫学 免疫学
- 神经学 神经学
背景情况:
- 急性甲状腺毒性肌肉病变 (ATM) 是甲状腺毒性病的严重,可能致命的并发症.
- 目前的ATM诊断依赖于临床症状,缺乏特定的血清学标记.
- 从临床上来说,将ATM与其他甲状腺疾病 (如Graves病) 区分开来是非常重要的.
研究的目的:
- 为了研究ATM,GD和健康对照患者的血清CD40水平.
- 评估CD40作为潜在的ATM诊断生物标志物.
- 评估血清CD40和ATM症状严重程度和甲状腺功能之间的相关性.
主要方法:
- 追溯横截面研究涉及17名ATM患者,17名GD患者和17名健康对照.
- 测量血清中的CD40,FT3,FT4,TSH,TGAb,TRAb和TPOAb水平. 这样可以测量血清中的CD40,FT3,FT4,TSH,TGAb,TRAb和TPOAb.
- 诊断值的接收器操作特征 (ROC) 曲线分析和关系的斯皮尔曼相关性.
主要成果:
- 与GD患者和对照组相比,ATM患者的血清CD40,FT3和FT4水平明显高于GD患者和对照组 (P <0.01).
- ROC分析显示,CD40在区分ATM和GD方面具有很高的预测值 (AUC=0.99,灵敏度=94.1%,特异性=94.1%).
- 血清CD40与ATM症状评分 (ATMSS) (r=0.72,P<0.01) 和甲状腺激素FT3和FT4.4正相关.
结论:
- 血清CD40水平升高与ATM有关,与症状严重程度相关.
- CD40显示出作为一种有价值的生物标志物,用于早期诊断和区分ATM的潜力.
- 这一发现为ATM的差异诊断和管理提供了新的见解.
相关概念视频
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
76
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
76
Myasthenia Gravis: Diagnostic Tests
593
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
593


